Navigation Links
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Date:6/16/2008

tudy of Voreloxin and Cytarabine Indicates Activity of Combination Regimen

Preliminary results were also presented today from Sunesis' ongoing dose-escalating Phase 1b clinical trial evaluating voreloxin in combination with cytarabine, the current standard of care in patients with relapsed and/or refractory AML. The Phase 1b trial is designed to evaluate the safety and tolerability, and to provide a preliminary assessment of anti-leukemic activity, of escalating doses of voreloxin when administered on days one and four with a fixed dose of 400 mg/m2/day of cytarabine given as a continuous infusion for five days. Of twelve evaluable patients in the first three cohorts, three patients have achieved CRs (one at 20 mg/m2 of voreloxin and two at 34 mg/m2 of voreloxin). Six patients were enrolled in cohort 4 (50 mg/m2 of voreloxin), and no dose limiting toxicities have been observed thus far at this dose. Patients are now being enrolled in cohort 5 at 70 mg/m2 of voreloxin. Voreloxin pharmacokinetics have so far been unaffected by the combination with cytarabine.

"We are very pleased by the interim results reported today from our Phase 1b combination study of voreloxin with cytarabine. We look forward to reporting results from this study later in the year, including CR rates at 50 mg/m2 and higher dose levels of voreloxin," continued Dr. Michelson.

These data were presented today in a poster titled "Safety and Efficacy Experience of Voreloxin (formerly SNS-595) in Relapsed/Refractory Acute Leukemia Patients >/= 60 Years Old Compared to <60 Years Old: Results of a Phase 1b Study" (Abstract #0515) at the 13th Congress of the European Hematology Association. A copy of the poster will be available on the Sunesis corporate website at http://www.sunesis.com.

About Voreloxin (formerly SNS-595)

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally re
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
4. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
5. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 - ... R egistry data presented at ESC ... on the evolution of manag ing AF ... -   The first-ever two-year outcomes from the Global ... 2015 expose that all-cause death was the most frequent major event in more ...
(Date:9/1/2015)... Norway , September 1, 2015 ... biopharmaceutical company, today announces that it has appointed ... as Non-Executive Directors to its Board of Directors, effective ... 30 years of experience in pharma and biotech and ... Genzyme, a Sanofi company. Previously her role was Vice ...
(Date:8/31/2015)... The Indiana Medical Device Manufacturers Council and ... Sciences Policy Forum to state legislators. The new policy ... Diagnostics in Indianapolis and featured ... Ellspermann and State Sen. Brandt Hershman . ... new Learning & Development Center, which is under construction ...
Breaking Medicine Technology:Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9BerGenBio Appoints Non-Executive Directors 2Indiana Lt. Gov. Sue Ellspermann and State Sen. Brandt Hershman Kick Off New Life Sciences Policy Series 2Indiana Lt. Gov. Sue Ellspermann and State Sen. Brandt Hershman Kick Off New Life Sciences Policy Series 3
... NEW YORK, Jan. 4, 2011 Reportlinker.com announces that a ... Cosmetic Surgery Products http://www.reportlinker.com/p060973/Cosmetic-Surgery-Products.html ... through 2014 Demand for products used in ... to $2.8 billion in 2014, when 16.1 million cosmetic procedures ...
... Jan. 3, 2011 Dynatronics Corporation (Nasdaq: ... of an agreement with Premier Purchasing Partners, L.P., the ... contracted supplier of physical therapy products and exercise equipment ... alternate market facilities.   Premier, Inc. is ...
Cached Medicine Technology:Reportlinker Adds Cosmetic Surgery Products 2Reportlinker Adds Cosmetic Surgery Products 3Dynatronics Named Contract Supplier to Premier, Inc. 2
(Date:9/1/2015)... ... September 01, 2015 , ... Stress comes in many different ... life changes can lead to very serious, life-altering events. Fortunately nature offers a ... Herbal supplement manufacturer MediHerb has coupled therapeutic doses of Rhodiola and ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... survey to aid colleges and universities across the country in stemming sexual assaults ... Researcher Campus Climate Collaborative (ARC3), a consortium of sexual assault researchers and student ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... that creates negative pressure inside a wound to remove exudates, fluid, and infectious ... devices (comprising portable devices, stand-alone devices, disposable devices, and canisters, etc.) is projected ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Jerry Segal Classic to ... Club and Green Valley Country Club in Lafayette Hill, PA. Over the past 26 ... $13.5 million for programs and services designed to support patients and their families during ...
(Date:9/1/2015)... ... ... Royal River Natural Foods, a locally-owned independent natural health store in Freeport, Maine, ... found that, among those who had a stroke, people who used multivitamins survived longer ... September 2015 issue of “Natural Insights for Well Being,” which Royal River Natural Foods ...
Breaking Medicine News(10 mins):Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... 19 Abbott announced today,that the U.S. ... the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for ... analyzer. , Cartridges for E3+, ... patient,s,metabolic state within a few minutes. The glucose ...
... Ipilimumab Will Earn Decision Resources, Clinical Gold Standard ... to a New Report from Decision ResourcesWALTHAM, Mass., ... of the world,s leading research and advisory firms ... drug for treating stage IV malignant melanoma that ...
... Frost & Sullivan to Host Quarterly Analyst Briefing ... 28 January 2009 LONDON, Jan. 19 The ... is pleased to announce its 2009 Quarterly Analyst ... to be held on Wednesday, 28 January, 2009 ...
... recall of approximately 322 cranial implant kits that were implanted in ... been recalled due to controversy on the sterility of the implants. ... ... LegalView.info, the number one source for anything and everything legal on ...
... Images that for the first time show bleeding inside the ... captured by scientists, in a new study published today in ... the amount of bleeding can indicate how damaged a person,s ... MRC Clinical Sciences Centre at Imperial College London, hope that ...
... Jan. 18 Days before national SEIU officials are ... Workers (UHW), an off-duty police officer apparently hired as ... union and assaulted a UHW staff member."Before I even ... was wrong," said Andrea Carol, a UHW member and ...
Cached Medicine News:Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 2Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 3Health News:A Stage IV Malignant Melanoma Drug That Increases Overall Survival Would Earn a Higher Patient Share in the U.S. Than in Europe 2Health News:Will the Economic Slowdown Affect the Medical Imaging Business Globally? 2Health News:LegalView Developing Cranial Implant Information Portal Detailing the Recall of Stryker Cranial Implant Kits 2Health News:LegalView Developing Cranial Implant Information Portal Detailing the Recall of Stryker Cranial Implant Kits 3Health News:Bleeding hearts revealed with new scan 2Health News:As SEIU Prepares Hostile Takeover of United Healthcare Workers, Surveillance of Local Union Office Ends in Assault by Off-Duty Police Officer 2Health News:As SEIU Prepares Hostile Takeover of United Healthcare Workers, Surveillance of Local Union Office Ends in Assault by Off-Duty Police Officer 3
... 1000 Power Instrument System is a ... versatility and convenience with modular and ... without hand throttle, for use with ... pedal. Accepts all 1000 and 2000 ...
... The Brasseler USA™ 2002 Battery Charger is manufactured ... The 2002 Battery Charger can charge up to ... minutes. The 2002 Charger is designed to operate ... there is a malfunction in the operation of ...
... diamond shaped teeth set the blade on a straight ... are very sharp, and the cut starts true, dancing ... with minimal force due to the sharp, smooth ground, ... , ,The troughs between the teeth provide ...
The High Speed Drill handpiece is a well-balanced, high performance drill that provides high speed for,bone sculpting, along with power for difficult osteotomies. Must be used with the 6401-000 foot ...
Medicine Products: